Neurological-Focused Pharmaceutical Company, Lundbeck, Continues Use of Medidata Clinical Cloud With Multi-Year Partnership
NEW YORK and COPENHAGEN-October 5, 2017-Medidata (NASDAQ: MDSO), a global provider of cloud-based solutions and data analytics for clinical research, today announced that pharmaceutical firm H. Lundbeck A/S (Lundbeck), has entered a multi-year partnership to continue its use of the Medidata Clinical Cloud® and utilize operational capabilities to power their next generation global clinical trials. The continued partnership allows Lundbeck to leverage integral parts of the Medidata Clinical Cloud platform that provide key capabilities in study conduct and site support, including Medidata Rave®, Coder®, and TSDV (Targeted Source Document Verification). A Medidata customer since 2007, Lundbeck is a global pharmaceutical company specializing in psychiatric and neurological disorders. By continuing its use of Medidata Rave®, a industry solution for capturing, managing, and reporting data, Coder®, and TSDV (Targeted Source Document Verification), Lundbeck will increase the quality of its clinical research efforts by more accurately evaluating clinical data, streamlining workflows, and ultimately, optimizing trial results. “We’re proud to be a long term partner to Lundbeck, an innovative organization bringing together deep industry expertise in drug development activities for neurological disorders,” said Mike Capone, chief operating officer at Medidata. “We look forward to continuing to power their mission to tackle unmet needs for patients living with serious medical conditions.”
About Medidata
Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 850 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers-from study design and planning through execution, management and reporting. Medidata Contacts Investor: Anthony D’Amico, Medidata Solutions, +1 732-767-4331,
adamico@mdsol.com
Media: Erik Snider, Medidata Solutions, +1 646-362-2997,
esnider@mdsol.com
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
